New biomarker panel could support colorectal cancer diagnosis

Colorectal cancer is the second most common cause of cancer death in the West, linked largely to a love of booze, red meat and high-fat food combined with a lack of exercise. Further, symptoms are of the kind that people often don't want to talk to their doctors about--such as changes in "bowel habits"--and screening is either costly, invasive or not very specific. All the more reason why there's a need for a panel of biomarkers.

In a study published in BMC Cancer, a team of Spanish researchers analyzed the genetic material from tumors at different stages and compared these against non-tumor samples. They found genes directly involved in cancer progression, creating a genetic biomarker panel of 7 genes that should be able to discriminate accurately between non-cancerous and cancerous samples.

A diagnosis of colorectal cancer need not be a death sentence, and the use of biomarkers could differentiate the disease from others that mimic the symptoms, meaning that patients could be treated much earlier and have a better potential outcome. Future work is planned to look at each stage of disease, and according to the researchers, this biomarker panel could constitute the basis of a new tool with strong potential for colorectal cancer diagnosis.

- see the paper (.pdf)

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.